So Entresto is ready to be rolled out in the US with a price tag of around $4,500 a year. Novartis has hinted at an outcomes-based pricing plan but there are no details of any scheme or how it ...

Sacubitril, valsartan; 6mg/6mg, 15mg/16mg; oral pellets in caps. Entresto Sprinkle is supplied as film-coated oral pellets are round, biconvex in shape, and provided in a hard capsule in the ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

Novartis' drugs, including heart failure medicine Entresto and breast cancer therapy Kisqali, are manufactured across 33 ...

With the new manufacturing capacity, 100% of its key medicines for U.S. patients will be made in the U.S., Novartis said late ...

The pharmaceutical sector has been making headlines for large-scale layoffs, department closures and clinical trial failures.

After Novartis’ patent on the blockbuster blood pressure medication Entresto was found invalid at the district court for covering technology that was developed after the patent was filed ...

Additionally, Novartis differentiates itself by its sheer number of blockbusters, including Entresto for heart failure and Cosentyx for autoimmune diseases. Also, it has generated a strong late ...

(Reuters) - Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from ...